Oncotarget Delivers Quality In-Depth Research Materials
January 5, 2017
Oncotarget is a platform for research in the oncology and related areas on a weekly basis. Since 2010, the publication has provided up-to-date, carefully researched papers and articles about oncology and other topics that are related to the research and treatment of oncology.
Such topics as Cardiology, Immunology/Microbiology, Endocrinology, Pharmacology, Neuropathology/Neuroscience, Geotarget/Aging, Metabolism and other pertinent subjects on Twitter can be included as they relate to the research and treatment in the oncology and cancer fields.
Headed by Editors-in-Chief, Mikhail V. Blagosklonny, and Andrei V. Gudkov, both of The Roswell Park Cancer Institute of Buffalo, NY, Oncotarget has become a major contributor to specific and detailed research on Endnote.com results in the cancer treatment discipline.
All articles are submitted to the Editorial Board where they are subjected to a peer review at https://www.linkedin.com/company/oncotarget. At least two peer editors evaluate the submitted articles so that the balance of integrity and excellence is always in the forefront of the process. It is required that the editors who are assigned the peer review are experts in the topic of discussion in the submitted article.
The authors are required to present their thesis clearly and the citations must be from credible sources, experiments, and quality facts that are thoroughly researched. It is important that new articles on DovePress have the brevity and uniqueness of fresh information and application and not a rehash of previous research. The emphasis is on moving the topic forward so new information can be brought forth for practical use.
Editors are very sensitive as to how the research articles are written so that opinions and reflections are not a part of the essay. Influences such as political leanings, prejudicial influence, religious subtleties, slander, gender issues, racial issues, and other outside and personal persuasions are not allowed to be a part of the articles.
Editors of Oncotarget are prohibited from using any part of submitted articles for their own use, and they are charged with the keeping of confidentiality of all material that is submitted. When the article is finally published, the readers are assured that they are getting the most current and unbiased information possible.
The approved articles are published on a weekly basis to make the newest information readily available at the earliest opportunity. This helps to move new research into the medical community which is timely for use in treatment and understanding in practical use.